A little-known Chinese company made a drug that beat the world’s biggest-selling medicine
China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend isn’t confined to Big Tech: It has been quietly happening in the ...
Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy
Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in Australia. AK138D1, a self-developed and ...
You thought only DeepSeek routed American titans? Wait, here's a little-known Chinese biotech company whose lung cancer drug could rattle big pharma; here's al…
Chinese biotech company Akeso developed a lung cancer drug Ivonescimab, which outperformed Merck's Keytruda in trials. This ...
中国日报网17h
Chinese company's drug beats world's biggest-selling medicine: media
Ivonescimab, the new drug, was found in a trial conducted in China to have bested Keytruda, the blockbuster medication ...
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer ...
It’s not just AI. China’s medicines are surprising the world, too
In recent months China’s progress in artificial intelligence has stunned the world. A quieter yet equally significant shift ...
Wall Street Journal1d
Akeso Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
CNN5d
Just like AI, China’s biotech is disrupting the world. Is the US ready?
How to craft the perfect maternity leave out of office message ...
BioWorld13d
Akeso’s IL-4Rα/ST2 bispecific antibody gains IND clearance in China
Akeso Inc. has received IND approval by China’s National Medical Products Administration (NMPA) for AK-139, an IL-4Rα/ST2 ...
Medindia13d
Akeso Announces IND Acceptance for AK139, a Bispecific Antibody Targeting IL-4Ra and ST2 for Respiratory and Skin Diseases
HK) ("Akeso" or the "Company") is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Administration (NMPA) for AK139, a ...
finanzen2d
Akeso's Partner Summit, Pfizer Collaborate To Evaluate Ivonescimab In Solid Tumor Settings
Akeso Inc. has announced that Summit Therapeutics Inc. (SMMT), its partner for ivonescimab, has entered into a clinical trial ...
Akeso, Inc.: Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy
Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment ...